Journal Information
Vol. 41. Issue 12.
Pages 703 (December 2005)
Vol. 41. Issue 12.
Pages 703 (December 2005)
Letters to the Editor
Full text access
Malignant Pleural Mesothelioma: Further Options
Visits
3556
E.J. Van Hezik
Chest Department, Walcheren Hospital, POB 3200, 4380 DD Vlissingen, The Netherlands
This item has received
Article information
Full text is only aviable in PDF
REFERENCES
[1]
I Isidro Montes, K Abu-Shams, E Alday, JL Carretero Sastre, J Ferrer Sancho, A Freixa Blanxart, et al.
Normativa sobre el asbestos y sus enfermedades pleuropulmonares.
Arch Bronconeumol, 41 (2005), pp. 153-168
[2]
NJ Vogelzang, JJ Rusthoven, J Symanowski, C Denham, E Kaukel, P Ruffie, et al.
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
J Clin Oncol, 21 (2003), pp. 2636-2644
[3]
AK Nowak, MJ Byrne, MJ Mill ward, JM Álvarez, BW Robinson.
Current chemo-therapeutic treatment of malignant pleural mesothelioma.
Expert Opin Pharmacother, 5 (2004), pp. 2441-2449
[4]
P Bunn Jr.
New investigative regimens and cytotoxic agents in thoracic cancers: gemcitabine and pemetrexed.
Oncology, 18 (2004), pp. 5-11
[5]
V Rusch.
Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?.
J Clin Oncol, 21 (2003), pp. 2636
[6]
Y Aelony.
Need for further information on pemetrexed study.
J Clin Oncol, 22 (2004), pp. 4234-4235
[7]
BWS Robinson, J Creaney, R Lake, et al.
Mesothelin-family proteins and diagnosis of mesothelioma.
Lancet, 362 (2003), pp. 1612-1616
Copyright © 2005. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)